Blog
RSS FeedPosted by Michael Wonder on 24 May 2026
Changes to PBS wholesale mark-up fees from 1 July 2026
22 May 2026 - A fact sheet on the new wholesale mark-up structure for PBS medicines supplied through community pharmacies is ...
Posted by Michael Wonder on 24 May 2026
Gazyva (obinutuzumab) receives positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritis
22 May 2026 - Roche Canada is pleased to share that on 6 May 2026, Canada's Drug Agency recommended Gazyva ...
Posted by Michael Wonder on 22 May 2026
More New Zealanders could benefit from funded vaccines from 2027
21 May 2026 - PHARMAC is proposing changes that would give more New Zealanders access to funded vaccines from 2027, ...
Posted by Michael Wonder on 18 May 2026
Pressure mounting to subsidise weight loss drugs
18 May 2026 - Two-thirds of Australian adults are overweight and many are at risk of heart failure. This plan could ...
Posted by Michael Wonder on 18 May 2026
Qalsody: new data has allowed for a reassessment by the HAS
21 April 2026 - The drug Qalsody (tofersen) aims to slow the progression of a rare genetic form of ALS (amyotrophic ...
Posted by Michael Wonder on 17 May 2026
New medicines may be out of reach of PBS patients as Australia fails to adapt to ‘seismic market shifts’
18 May 2026 - Donald Trump’s medicines prices policy is causing global market disruption even as Australia’s broken approval processes leave ...
Posted by Michael Wonder on 15 May 2026
SMC - May 2026 decisions
11 May 2026 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...
Posted by Michael Wonder on 15 May 2026
Wegovy and Mounjaro for weight loss not funded
14 May 2026 - PHARMAC has assessed the application to fund Wegovy for weight loss and added it to our ...
Posted by Michael Wonder on 15 May 2026
Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families
14 May 2026 - People living with spinal muscular atrophy in England are set to gain routine access to two potentially ...
Posted by Michael Wonder on 15 May 2026
Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer
14 May 2026 - Over 1,500 people set to benefit from first immunotherapy for aggressive stomach cancer. ...
Posted by Michael Wonder on 09 May 2026
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia in Germany
6 May 2026 - The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and ...
Posted by Michael Wonder on 09 May 2026
Update from the PBAC (April 2026)
7 May 2026 - The PBAC has published its April 2026 update. ...
Posted by Michael Wonder on 08 May 2026
Update to agenda for the July 2026 PBAC meeting (8 May 2026)
8 May 2026 - The agenda for the July 2026 PBAC meeting has now been updated. ...
Posted by Michael Wonder on 08 May 2026
NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed
8 May 2026 - Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following ...
Posted by Michael Wonder on 05 May 2026
Expert says treatment relieves children's suffering and saves hospital resources
5 May 2026 - The family of an eight year old Sunshine Coast girl is petitioning the federal government to ...